Triptorelin Market Size & Share 2023 to 2032
Market Size by Drug (Triptorelin Pamoate, Triptorelin Acetate, Triptorelin Embonate), by Application (Cancer, Radical Prostatectomy, Central Precocious Puberty, Endometriosis), Product Form, Route Of Administration, by Distribution Channel & Global Forecast.
Report ID: GMI5427
|
Published Date: February 2023
|
Report Format: PDF
Download Free PDF
Authors:
Monali Tayade, Jignesh Rawal
Triptorelin Market Size
Triptorelin Market size was valued at over USD 910 million in 2022. Driven by the growing occurrence of endometriosis across the global female population, industry is expected to grow at over 5% CAGR from 2023 to 2032.
Triptorelin Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
Endometriosis is a disease that leads to scar tissue formation within the pelvis due to a chronic inflammatory response caused by the presence of endometrium outside the uterus. As per estimates, around 176 million women across the globe, around one in ten, suffer from endometriosis in their reproductive years, typically between the ages of 15 and 49. Triptorelin is efficacious in alleviating the pain symptoms caused by endometriosis. It has a favorable safety profile and has also been shown to improve reproductive function. Subsequently, it is commonly used to treat deep infiltrating endometriosis (DIE) among women.
Steep prices of triptorelin drugs may hamper industry outlook
Despite an extensive customer pool, triptorelin market faces a major challenge in the form of the high manufacturing cost of triptorelin drugs, which translates into steep medication prices for customers. Given that the raw materials utilized are specific to the drug, the quality of raw materials used in drug development is crucial, which further elevates costs. Meanwhile, the complexity of triptorelin manufacturing process, which entails a wide range of biological or chemical processes, is also impeding product adoption by limiting product availability to those who can afford it.
Triptorelin Market Analysis
Based on drug, triptorelin market share from triptorelin embonate segment is anticipated to grow at over 5% CAGR from 2023 to 2032, driven primarily by the growing number of prostate cancer cases worldwide. According to Global Cancer Observatory, GLOBOCAN, over 1.4 million prostate cancer cases were reported worldwide in 2020. Triptorelin embonate sees high demand owing to its efficacy in the treatment of advanced prostate cancer.
The intramuscular administration of 22.5 grams of triptorelin embonate in a 6-month formulation among men with advanced prostate cancer has been shown to initially increase their serum testosterone levels. It is also generally well-tolerated in such patients and has only mild severity of adverse reactions.
With respect to application, cancer segment accounted for more than 25% of the overall triptorelin industry share in 2022, on account of growing prevalence of cancer across the globe. As per WHO, cancer is the leading cause of death around the world and was responsible for nearly 10 million deaths in 2020. Prostate cancer, especially, is pegged to lead the charge by notably elevating the demand for triptorelin-based drugs. According to recent estimates from the American Cancer Society, the US is likely to record over 288,300 new cases of prostate cancer in 2023 alone.
Based on the route of administration, triptorelin market share from intradermal segment is likely to grow at over 4.5% CAGR from 2023 to 2032, fueled by the growing number of hormone therapies performed annually across the globe. Intradermal injections are widely utilized in such therapeutic procedures, which fosters the segment demand. They can also be used in TB tests, sensitivity tests for allergies, local anesthetic, and others. Intradermal delivery of vaccines is more efficient than injection into the subcutaneous tissue or muscle and reduces the antigen volume.
Europe triptorelin market is anticipated to reach a valuation of more than USD 370 million by 2032, owing to numerous industry players focusing on expanding their footprint across several European countries. Meanwhile, Europe is also increasingly investing on the health and well-being of its citizens to effectively address the increasing occurrence of endometriosis, cancer in the region. In fact, the region reports over 1.9 million deaths and 3.7 million new cases of cancer annually, making the disease its second leading cause of death and morbidity. In addition, rising disposable income has proliferated the demand for triptorelin-based drugs by bringing them in reach of more customers.
Triptorelin Market Share
Some prominent triptorelin market players include
Many of these companies are emphasizing partnership and collaborations to expand their industry influence. Citing an instance, Amneal Pharmaceuticals, an American pharma company, announced a long-term partnership agreement with Orion Corporation, a Finnish pharma company in January 2023, to commercialize many of Amneal’s complex generic products.
Through this agreement, the company’s complex generic programs will be displayed by Orion in New Zealand, Australia, and most parts of Europe. It will help the company reinforce its product portfolio in Europe.
Impact of the COVID-19 pandemic
COVID-19 pandemic resulted in changes in buying and stocking patterns, R&D processes, regulations, and demand, and supply shortages. The stockpiling of pharmaceutical products by stakeholders declined sales in the initial few months of 2020. It negatively affected the pharmaceutical and healthcare sector. The short-term implications of the pandemic on the industry were mixed. However, the market is set to flourish due to growing demand for few pharmaceutical products and rising acceptance of active pharma ingredients including triptorelin in drug development.
The triptorelin market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue in USD from 2018 to 2032 for the following segments:
Click here to Buy Section of this Report
By Drug
By Product Form
By Application
By Route of Administration
By Distribution Channel
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →